{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:28:45Z","timestamp":1791084525040,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02091-0","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:06:11Z","timestamp":1775736371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pentraxin 3 levels in polycystic ovary syndrome: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Reza","family":"Mohammadpour Fard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadese","family":"Nadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Kazemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Radmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Hosseinpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Sakhavarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-1205","authenticated-orcid":false,"given":"Seyed Sobhan","family":"Bahreiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"3","key":"2091_CR1","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"KM Hoeger","year":"2021","unstructured":"Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2091_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/09513590.2021.1958310","volume":"37","author":"J Coll\u00e9e","year":"2021","unstructured":"Coll\u00e9e J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol. 2021;37(10):869\u201374.","journal-title":"Gynecol Endocrinol"},{"key":"2091_CR3","doi-asserted-by":"crossref","unstructured":"Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Archives of gynecology and obstetrics. 2024;310(3):1303\u201314.","DOI":"10.1007\/s00404-024-07607-x"},{"issue":"2","key":"2091_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/clinem\/dgab613","volume":"107","author":"C Riestenberg","year":"2022","unstructured":"Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health care-related economic burden of polycystic ovary syndrome in the United States: pregnancy-related and long-term health consequences. J Clin Endocrinol Metab. 2022;107(2):575\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"2091_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1017468","volume":"13","author":"RH Emanuel","year":"2022","unstructured":"Emanuel RH, Roberts J, Docherty PD, Lunt H, Campbell RE, M\u00f6ller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol. 2022;13:1017468.","journal-title":"Front Endocrinol"},{"issue":"1","key":"2091_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.37745\/ejbmsr.2013\/vol11n15791","volume":"11","author":"S Karkera","year":"2023","unstructured":"Karkera S, Agard E, Sankova L. The clinical manifestations of polycystic ovary syndrome (PCOS) and the treatment options. Eur J Biol Med Sci Res. 2023;11(1):57\u201391.","journal-title":"Eur J Biol Med Sci Res"},{"issue":"5","key":"2091_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467\u2013520.","journal-title":"Endocr Rev"},{"issue":"3","key":"2091_CR8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1210\/jc.2005-2501","volume":"91","author":"S Franks","year":"2006","unstructured":"Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91(3):786\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2091_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00404-015-3889-5","volume":"293","author":"AS Jamil","year":"2016","unstructured":"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447\u201356.","journal-title":"Arch Gynecol Obstet"},{"key":"2091_CR10","doi-asserted-by":"crossref","unstructured":"Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. Journal of hepatology. 2016;64(6):1416\u201327.","DOI":"10.1016\/j.jhep.2016.02.029"},{"issue":"1","key":"2091_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01849-8","volume":"17","author":"R Mohammadpour Fard","year":"2025","unstructured":"Mohammadpour Fard R, Sherafat NS, Rashno M, Bahreiny SS. Evaluating pentraxin 3 as a diagnostic biomarker for diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17(1):273.","journal-title":"Diabetol Metab Syndr"},{"key":"2091_CR12","doi-asserted-by":"crossref","unstructured":"Doni A, Stravalaci M, Inforzato A, Magrini E, Mantovani A, Garlanda C, et al. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Frontiers in Immunology. 2019;10:712.","DOI":"10.3389\/fimmu.2019.00712"},{"key":"2091_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02808","volume":"9","author":"A Camaioni","year":"2018","unstructured":"Camaioni A, Klinger FG, Campagnolo L, Salustri A. The influence of pentraxin 3 on the ovarian function and its impact on fertility. Front Immunol. 2018;9:2808.","journal-title":"Front Immunol"},{"issue":"5","key":"2091_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10815-021-02105-4","volume":"38","author":"J Pan","year":"2021","unstructured":"Pan J, Zhou C, Zhou Z, Yang Z, Dai T, Huang H, et al. Elevated ovarian pentraxin 3 in polycystic ovary syndrome. J Assist Reprod Genet. 2021;38(5):1231\u20137.","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"2091_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00886-4","volume":"21","author":"C Jin","year":"2021","unstructured":"Jin C, Zou K, Xu Y, Yang H, Pan J. Elevated plasma pentraxin-3 in polycystic ovary syndrome is associated with hyperandrogenism: a case-control study. BMC Endocr Disord. 2021;21(1):240.","journal-title":"BMC Endocr Disord"},{"issue":"42","key":"2091_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040155","volume":"103","author":"FT \u00c7a\u011f\u0131ran","year":"2024","unstructured":"\u00c7a\u011f\u0131ran FT, Mavral N, Kal\u0131 Z, Ecin SM. Serum pentraxin-3 expression varies according to polycystic ovary syndrome phenotypes. Medicine (Baltimore). 2024;103(42):e40155.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2091_CR17","doi-asserted-by":"publisher","DOI":"10.31083\/j.ceog4902038","volume":"49","author":"F Ye\u015fil","year":"2022","unstructured":"Ye\u015fil F, Deveci K, Karli P. Evaluation of the clinical significance of serum pentraxin-3 levels in patients with polycystic ovary syndrome. Clin Exp Obstet Gynecol. 2022;49(2):38.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"2091_CR18","doi-asserted-by":"crossref","unstructured":"Shnain ZK, Al-Fartosy AJM. Circular Pentraxin-3 and Betatrophin as Novel Predictors and Promising Biomarkers in Polycystic Ovary Syndrome with or without Type 2 Diabetes Mellitus. South Eastern European Journal of Public Health. 2024:105\u201314.","DOI":"10.70135\/seejph.vi.963"},{"key":"2091_CR19","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","DOI":"10.1016\/j.ijsu.2021.105906"},{"issue":"2","key":"2091_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","volume":"38","author":"JH Schiavo","year":"2019","unstructured":"Schiavo JH. PROSPERO: an international register of systematic review protocols. Med Ref Serv Q. 2019;38(2):171\u201380.","journal-title":"Med Ref Serv Q"},{"key":"2091_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:1\u201313.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2091_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-11-109","volume":"11","author":"X Huang","year":"2013","unstructured":"Huang X, Hao C, Shen X, Zhang Y, Liu X. RUNX2, GPX3 and PTX3 gene expression profiling in cumulus cells are reflective oocyte\/embryo competence and potentially reliable predictors of embryo developmental competence in PCOS patients. Reprod Biol Endocrinol. 2013;11(1):109.","journal-title":"Reprod Biol Endocrinol"},{"issue":"6","key":"2091_CR23","first-page":"812","volume":"18","author":"Y Song","year":"2024","unstructured":"Song Y, Gao J, Huang X, Zhang D, Wang D. Expression of PTX-3 and COX-2 in patients with polycystic ovary syndrome and their relationship with insulin resistance. Chin J Endocrine Surg. 2024;18(6):812\u20137.","journal-title":"Chin J Endocrine Surg"},{"issue":"02","key":"2091_CR24","first-page":"119","volume":"37","author":"X Pan","year":"2025","unstructured":"Pan X. \u8840\u6e05CTRP9\u3001Asprosin\u3001PTX3\u6c34\u5e73\u5355\u9879\u53ca\u8054\u5408\u68c0\u6d4b\u8bca\u65ad\u591a\u56ca\u5375\u5de2\u7efc\u5408\u5f81\u7684\u6548\u80fd [Efficiencies of single and combined detection of serum CTRP9, Asprosin and PTX3 levels in diagnosis of polycystic ovary syndrome]. Medical Journal of Chinese People\u2019s Health. 2025;37(02):119\u201321.","journal-title":"Medical Journal of Chinese People's Health"},{"key":"2091_CR25","doi-asserted-by":"crossref","unstructured":"Li Y, Huang Y, Peng J, Man Y, Li Y, Peng E, et al. Correlation of Serum Pentraxin 3, Apelin and sRAGE with Obesity and Glycolipid Metabolism in Polycystic Ovary Syndrome. Pakistan Journal of Zoology. 2024;56:3601\u20134.","DOI":"10.17582\/journal.pjz\/20230319170342"},{"issue":"08","key":"2091_CR26","first-page":"1183","volume":"26","author":"R Song","year":"2022","unstructured":"Song R. \u591a\u56ca\u5375\u5de2\u7efc\u5408\u5f81\u60a3\u8005\u8840\u6e05PTX3\u3001MMP-9\u8868\u8fbe\u7684\u4e34\u5e8a\u610f\u4e49 [Clinical significance of serum PTX3 and MMP-9 expressions in patients with polycystic ovary syndrome]. Chin J Lab Diagn. 2022;26(08):1183\u20135.","journal-title":"Chin J Lab Diagn"},{"issue":"01","key":"2091_CR27","first-page":"90","volume":"31","author":"J Guo","year":"2022","unstructured":"Guo J, Li X. \u591a\u56ca\u5375\u5de2\u7efc\u5408\u5f81\u60a3\u8005\u8840\u6e05\u4e94\u805a\u7d203\u6c34\u5e73\u4e0e\u80f0\u5c9b\u7d20\u62b5\u6297\u53ca\u708e\u75c7\u72b6\u6001\u7684\u5173\u7cfb [Relationship Between the Level of Serum Pentraxin 3 and Insulin Resistance and Inflammatory State in Patients with Polycystic Ovary Syndrome]. Henan Yi Xue Yan Jiu. 2022;31(01):90\u20133.","journal-title":"Henan Yi Xue Yan Jiu"},{"issue":"06","key":"2091_CR28","first-page":"883","volume":"51","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Hu H, Wang Y. \u521d\u8bca\u591a\u56ca\u5375\u5de2\u7efc\u5408\u5f81\u60a3\u8005\u7a7a\u8179\u8840\u6e05Pentraxin3\u7684\u6c34\u5e73\u53d8\u5316\u53ca\u610f\u4e49 [Changes and significance of fasting serum Pentraxin3 levels in patients with newly-diagnosed polycystic ovarian syndrome]. Acta Univ Med Anhui. 2016;51(06):883\u20137.","journal-title":"Acta Univ Med Anhui"},{"key":"2091_CR29","doi-asserted-by":"crossref","unstructured":"Deveer M, Deveer R, Basaran O, Turkcu UO, Akbaba E, Cullu N, et al. Serum copeptin, pentraxin 3, anti-mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome. Journal of clinical medicine research. 2015;7(12):989.","DOI":"10.14740\/jocmr2375w"},{"issue":"3","key":"2091_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000363744","volume":"78","author":"U Sari","year":"2014","unstructured":"Sari U, Kaygusuz I, Kafali H. Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome? Gynecol Obstet Invest. 2014;78(3):173\u20138.","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"2091_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1721727X1401200115","volume":"12","author":"N G\u00fcd\u00fcc\u00fc","year":"2014","unstructured":"G\u00fcd\u00fcc\u00fc N, G\u00f6rm\u00fc\u015f U, Alp E, Kavak ZN, D\u00fcnder \u0130. Reciprocal action of pentraxin-3 and Crp in women with polycystic ovary syndrome. Eur J Inflamm. 2014;12(1):161\u20136.","journal-title":"Eur J Inflamm"},{"key":"2091_CR32","unstructured":"Sahin FK, Sahin SB, Balik G, Ural UM, Tekin YB, Cure MC, et al. Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity? International Journal of Clinical and Experimental Medicine. 2014;7(10):3512."},{"key":"2091_CR33","doi-asserted-by":"crossref","unstructured":"Aydogdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Meric C, et al. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology. 2012;28(9):722\u20135.","DOI":"10.3109\/09513590.2011.652719"},{"issue":"2","key":"2091_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.36129\/jog.2023.132","volume":"36","author":"NS Essa","year":"2024","unstructured":"Essa NS, Hameed BH. Assessment of the long Pentraxin 3 level in polycystic ovarian syndrome-related infertility. Ital J Gynaecol Obstet. 2024;36(2):247\u201355.","journal-title":"Ital J Gynaecol Obstet"},{"key":"2091_CR35","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Moncayo S, Insenser M, Montes-Nieto R, Fern\u00e1ndez-Dur\u00e1n E, \u00c1lvarez-Blasco F, et al. Postprandial inflammatory responses after oral glucose, lipid and protein challenges: Influence of obesity, sex and polycystic ovary syndrome. Clinical Nutrition. 2020;39(3):876\u201385.","DOI":"10.1016\/j.clnu.2019.03.027"},{"key":"2091_CR36","doi-asserted-by":"crossref","unstructured":"Wyskida K, Franik G, Chor\u0119za P, Pohl N, Markuszewski L, Owczarek A, et al. Pentraxin 3 levels in young women with and without polycystic ovary syndrome (PCOS) in relation to the nutritional status and systemic inflammation. International journal of endocrinology. 2020;2020(1):1380176.","DOI":"10.1155\/2020\/1380176"},{"issue":"3","key":"2091_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1530\/EJE-13-0761","volume":"170","author":"F Tosi","year":"2014","unstructured":"Tosi F, Di Sarra D, Bonin C, Zambotti F, Dall\u2019Alda M, Fiers T, et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. Eur J Endocrinol. 2014;170(3):401\u20139.","journal-title":"Eur J Endocrinol"},{"key":"2091_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","volume":"182","author":"S Patel","year":"2018","unstructured":"Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27\u201336.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2091_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygcen.2017.12.007","volume":"260","author":"N Malini","year":"2018","unstructured":"Malini N, George KR. Evaluation of different ranges of LH: FSH ratios in polycystic ovarian syndrome (PCOS)\u2013clinical based case control study. Gen Comp Endocrinol. 2018;260:51\u20137.","journal-title":"Gen Comp Endocrinol"},{"key":"2091_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.685724","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liu H, Li Z, Fan H, Yan X, Liu X, et al. The release of peripheral immune inflammatory cytokines promote an inflammatory cascade in PCOS patients via altering the follicular microenvironment. Front Immunol. 2021;12:685724.","journal-title":"Front Immunol"},{"issue":"6","key":"2091_CR41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/biolre\/ioab050","volume":"104","author":"LM Velez","year":"2021","unstructured":"Velez LM, Seldin M, Motta AB. Inflammation and reproductive function in women with polycystic ovary syndrome. Biol Reprod. 2021;104(6):1205\u201317.","journal-title":"Biol Reprod"},{"issue":"4","key":"2091_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.30699\/jogcr.9.4.422","volume":"9","author":"SH Al-Mayoofee","year":"2024","unstructured":"Al-Mayoofee SH, Missaoui N, Hmissa S, Al-Snafi AE. Adipokines in relation to weight, lipid profile and glycemic state in women with polycystic ovary syndrome. Journal of Obstetrics, Gynecology and Cancer Research. 2024;9(4):422\u20137.","journal-title":"Journal of Obstetrics, Gynecology and Cancer Research"},{"issue":"12","key":"2091_CR43","first-page":"943","volume":"22","author":"SS Bahreiny","year":"2025","unstructured":"Bahreiny SS, Ahangarpour A, Harooni E, Amraei M, Aghaei M, Fard RM. Closer look at circulating nitric oxide levels and their association with polycystic ovary syndrome: a meta-analytical exploration. International Journal of Reproductive BioMedicine. 2025;22(12):943.","journal-title":"International Journal of Reproductive BioMedicine"},{"issue":"6","key":"2091_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061567","volume":"11","author":"AM Kici\u0144ska","year":"2023","unstructured":"Kici\u0144ska AM, Maksym RB, Zabielska-Kaczorowska MA, Stachowska A, Babi\u0144ska A. Immunological and metabolic causes of infertility in polycystic ovary syndrome. Biomedicines. 2023;11(6):1567.","journal-title":"Biomedicines"},{"key":"2091_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.domaniend.2016.01.004","volume":"56","author":"E Nagyova","year":"2016","unstructured":"Nagyova E, Kalous J, Nemcova L. Increased expression of pentraxin 3 after in vivo and in vitro stimulation with gonadotropins in porcine oocyte-cumulus complexes and granulosa cells. Domest Anim Endocrinol. 2016;56:29\u201335.","journal-title":"Domest Anim Endocrinol"},{"issue":"1","key":"2091_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13048-024-01404-5","volume":"17","author":"Y Li","year":"2024","unstructured":"Li Y, Chang H-M, Zhu H, Sun Y-P, Leung PC. EGF-like growth factors upregulate pentraxin 3 expression in human granulosa-lutein cells. J Ovarian Res. 2024;17(1):97.","journal-title":"J Ovarian Res"},{"key":"2091_CR47","doi-asserted-by":"crossref","unstructured":"Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. 2004.","DOI":"10.1242\/dev.01056"},{"key":"2091_CR48","doi-asserted-by":"crossref","unstructured":"Scarchilli L, Camaioni A, Bottazzi B, Negri V, Doni A, Deban L, et al. PTX3 Interacts with Inter-\u03b1-trypsin Inhibitor: IMPLICATIONS FOR HYALURONAN ORGANIZATION AND CUMULUS OOPHORUS EXPANSION*\u2666. Journal of Biological Chemistry. 2007;282(41):30161\u201370.","DOI":"10.1074\/jbc.M703738200"},{"key":"2091_CR49","doi-asserted-by":"crossref","unstructured":"Zalman Y, Klipper E, Farberov S, Mondal M, Wee G, Folger JK, et al. Regulation of angiogenesis-related prostaglandin f2alpha-induced genes in the bovine corpus luteum. Biology of reproduction. 2012;86(3):92, 1\u201310.","DOI":"10.1095\/biolreprod.111.095067"},{"key":"2091_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02327","volume":"9","author":"M Presta","year":"2018","unstructured":"Presta M, Foglio E, Churruca Schuind A, Ronca R. Long pentraxin-3 modulates the angiogenic activity of fibroblast growth factor-2. Front Immunol. 2018;9:2327.","journal-title":"Front Immunol"},{"key":"2091_CR51","doi-asserted-by":"crossref","unstructured":"Basile A, Sica A, d\u2019Aniello E, Breviario F, Garrido G, Castellano M, et al. Characterization of the promoter for the human long pentraxin PTX3: role of NF-\u03baB in tumor necrosis factor-\u03b1 and interleukin-1\u03b2 regulation. Journal of Biological Chemistry. 1997;272(13):8172\u20138.","DOI":"10.1074\/jbc.272.13.8172"},{"issue":"1","key":"2091_CR52","volume":"2012","author":"P Kunes","year":"2012","unstructured":"Kunes P, Holubcova Z, Kolackova M, Krejsek J. Pentraxin 3 (PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012;2012(1):920517.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"2091_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ni.1854","volume":"11","author":"L Deban","year":"2010","unstructured":"Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328\u201334.","journal-title":"Nat Immunol"},{"issue":"1","key":"2091_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep42195","volume":"7","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, He H, Mukai S, Imada T, Nakamura S, Su C-W, et al. Heavy chain-hyaluronan\/pentraxin 3 from amniotic membrane suppresses inflammation and scarring in murine lacrimal gland and conjunctiva of chronic graft-versus-host disease. Sci Rep. 2017;7(1):42195.","journal-title":"Sci Rep"},{"issue":"4","key":"2091_CR55","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1093\/ejendo\/lvaf062","volume":"192","author":"E Vale-Fernandes","year":"2025","unstructured":"Vale-Fernandes E, Pignatelli D, Monteiro MP. Should anti-M\u00fcllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons. Eur J Endocrinol. 2025;192(4):R29\u201343.","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02091-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:07:14Z","timestamp":1779350834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02091-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}